Brief: NLS Pharmaceutics Announces Preclinical Data Demonstrating The Potential Of NLS-4 (Lauflumide) To Treat Chronic Fatigue Associated With Long-Covid
14/10/2021 13:41
Oct 14 (Reuters) - NLS Pharmaceutics AG NLSP.O :
* NLS PHARMACEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING
THE
POTENTIAL OF NLS-4 (LAUFLUMIDE) TO TREAT CHRONIC FATIGUE
ASSOCIATED WITH LONG-COVID
* NLS PHARMACEUTICS AG - NLS-4 (LAUFLUMIDE) HAS SHOWN
PROMISE FOR
TREATMENT OF CHRONIC FATIGUE ASSOCIATED WITH LONG-COVID
Further company coverage: NLSP.O
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing